Ignite Creation Date:
2025-12-24 @ 11:58 PM
Ignite Modification Date:
2025-12-25 @ 9:55 PM
Study NCT ID:
NCT02886858
Status:
TERMINATED
Last Update Posted:
2019-04-22
First Post:
2016-08-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
tDCS in the Prevention of Relapse After Electroconvulsive Therapy
Sponsor:
Hôpital le Vinatier
Organization:
Study Overview
Official Title:
tDCS as Continuation Treatment to Sustain Remission After Electroconvulsive Therapy in Depression
Status:
TERMINATED
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
investigator and sponsor decided by mutual agreement to stop study prematurely
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
While electroconvulsive therapy (ECT) in major depression is effective, high relapse rates and cognitive side effects limit its long-term use. There is no consensus about optimal continuation pharmacological treatments after a ECT course.
Adjunction of tDCS to pharmacological continuation treatment after ECT may decrease relapse rates.
Adjunction of tDCS to pharmacological continuation treatment after ECT may decrease relapse rates.
Detailed Description:
In a prospective, randomized, double blind, controlled, long-term study, investigators assign 40 depressed patients, in remission after ECT course associated to venlafaxine, with lithium adjunction after ECT course, either to tDCS or sham tDCS. Depressive symptoms and cognition were assessed after acute ECT after six months of continuation therapy.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: